4.9.5.3Vertical
Genetic & Molecular Testing
Labs performing DNA, RNA, and genomic diagnostic tests.
Market snapshot
These figures describe Laboratory & Diagnostic Services (4.9.5), the segment that Genetic & Molecular Testing sits within — not Genetic & Molecular Testing on its own.
- Market size
- ~$76B
- Growth
- ~10.1%CAGR (2017–22, nominal)
- Companies
- ~14,900
FragmentationConsolidatingEstimate
U.S. Census Bureau 2022 CBP/Economic Census, NAICS 621511 (Medical Laboratories) + 621991 (Blood & Organ Banks); 2022 figures are inflated by the COVID-testing surge.
Business model & economics
Revenue model
Per-test reimbursement across clinical and specialty testing
Key economics
- Recurring revenue
- Moderate–High
- EBITDA margin
- 15–25%
- Capex intensity
- High
recurring testing volume
Characteristics
- Reference-lab market consolidated around Labcorp and Quest.
- COVID-testing surge inflated 2020–22, then normalized.
- Molecular and genetic testing the durable growth driver.
M&A deal context
Deal activityHigh
Who’s acquiring
- Reference-lab majors
- Genomic & specialty-testing acquirers
- PE-backed lab consolidators
What’s driving deals
- Acquisition of hospital outreach and specialty labs.
- Molecular and precision-diagnostics growth.
- Consolidation around scaled reference labs.
Find Genetic & Molecular Testing acquisition targets
Search Acquisera’s index for companies classified under Genetic & Molecular Testing (4.9.5.3) and build a targeted deal pipeline.
Search companies